PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Peter Palese to Keynote at Influenza Research & Development Meeting, July 9-10, San Francisco, California - Peter Palese, Professor and Chair, Department of Microbiology, Mount Sinai School of Medicine, will be giving a keynote presentation entitled “A Universal Influenza Virus Vaccine” at the Influenza Research and Development Conference on July 9th-10th - GTC
Peter Palese to Keynote at Influenza Research & Development Meeting, July 9-10, San Francisco, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2012/06/12 - Peter Palese, Professor and Chair, Department of Microbiology, Mount Sinai School of Medicine, will be giving a keynote presentation entitled “A Universal Influenza Virus Vaccine” at the Influenza Research and Development Conference on July 9th-10th - GTC.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Influenza virus infection continues to be a major public health problem worldwide. Available influenza virus vaccines are effective in healthy individuals but are usually re-formulated annually due to antigenic drift of the circulating viruses. Thus, influenza vaccination programs requiring yearly reimmunization are both expensive and difficult to implement. Recent reports on broadly neutralizing anti-influenza hemagglutinin antibodies suggest that eliciting broad-spectrum humoral immunity against influenza viruses should be possible, given the right immunogen.
Most broadly neutralizing anti-influenza hemagglutinin antibodies bind to the conserved but immuno-subdominant stalk region of the hemagglutinin molecule. Such stalk-specific antibodies directed against the sub-dominant domain of the hemagglutinin have also been found responsible for the extinction of the seasonal H1N1 influenza viruses after the pandemic H1N1 viruses appeared in 2009. In order to induce such antibodies via vaccination, we have designed different hemagglutinin-based immunogens.

These novel constructs (for example, headless hemagglutinins, chimeric hemagglutinins) direct the immune response against the stalk domain efficiently boosting a cross-reactive immune response. Preliminary data from heterologous virus challenge experiments in mice suggest that these novel vaccine constructs are able to induce high levels of broadly neutralizing antibodies that protect against morbidity and mortality. The development of a universal influenza virus vaccine, that - similar to the existing polio and measles vaccines - requires a single or only a few immunizations represents a major advance towards the control of influenza worldwide.

Benefits of this talk include:

1) Chimeric Influenza Viruses as analytical tools;
2) Extinction of seasonal influenza viruses by pandemic strains;
3) Hemagglutinin stem antibodies;
4) Heterosubtypic protection.

Dr. Palese is Professor of Microbiology and Chair of the Department of Microbiology at the Mount Sinai School of Medicine in New York. He established the first genetic maps for influenza A, B and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals). Dr. Palese also pioneered the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. This technique is crucial for the study of the structure/function relationships of viral genes, for investigation of viral pathogenicity and for development and manufacture of novel vaccines. Dr. Palese was elected to the National Academy of Sciences in 2000 for his seminal studies on influenza viruses.

GTC’s Influenza Research & Development is a two-day conference that will be held at the San Francisco Airport Marriott Waterfront. This conference will cover various aspects of basic research in influenza including correlates of protection, the role of t-cells in influenza, antibodies, adjuvants and vaccination. Topics such as the current threat of the H5N1 virus and updates on the universal influenza vaccine will be covered by key academic researchers and leaders of the industry. Additionally, government representatives from BARDA, FDA and the USAID will discuss regulatory and government policies for vaccinations in conjunction with our 10th Vaccines Research and Development: All Things Considered Conference.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Peter Palese to Keynote at Influenza Research & Development Meeting, July 9-10, San Francisco, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 ken.lin[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)